JPWO2021241616A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021241616A5 JPWO2021241616A5 JP2022526603A JP2022526603A JPWO2021241616A5 JP WO2021241616 A5 JPWO2021241616 A5 JP WO2021241616A5 JP 2022526603 A JP2022526603 A JP 2022526603A JP 2022526603 A JP2022526603 A JP 2022526603A JP WO2021241616 A5 JPWO2021241616 A5 JP WO2021241616A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- human
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020092105 | 2020-05-27 | ||
| PCT/JP2021/019929 WO2021241616A1 (ja) | 2020-05-27 | 2021-05-26 | 抗ヒトｎｒ１抗体誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021241616A1 JPWO2021241616A1 (https=) | 2021-12-02 |
| JPWO2021241616A5 true JPWO2021241616A5 (https=) | 2024-06-05 |
Family
ID=78744563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526603A Pending JPWO2021241616A1 (https=) | 2020-05-27 | 2021-05-26 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230220070A1 (https=) |
| EP (1) | EP4159859A4 (https=) |
| JP (1) | JPWO2021241616A1 (https=) |
| KR (1) | KR20230029671A (https=) |
| CN (2) | CN120737200A (https=) |
| AU (1) | AU2021281828A1 (https=) |
| BR (1) | BR112022023931A2 (https=) |
| CA (1) | CA3180470A1 (https=) |
| IL (1) | IL298537A (https=) |
| MX (1) | MX2022014856A (https=) |
| WO (1) | WO2021241616A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021241616A1 (ja) | 2020-05-27 | 2021-12-02 | アステラス製薬株式会社 | 抗ヒトｎｒ１抗体誘導体 |
| JP7730432B2 (ja) | 2022-10-19 | 2025-08-27 | アステラス製薬株式会社 | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
| AU2024242885A1 (en) * | 2023-03-30 | 2025-09-11 | Arialys Therapeutics, Inc. | Detection of autoantibodies against nr1 |
| WO2026033259A1 (en) * | 2024-08-05 | 2026-02-12 | Lys Therapeutics | Antibodies for treating neurological and neurovascular disorders |
| WO2026044177A1 (en) * | 2024-08-23 | 2026-02-26 | Janssen Biotech, Inc. | Methods of treatment with gprc5d antibodies with enhanced effector function |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| PT1718677E (pt) * | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| EP2805972A1 (en) | 2013-05-21 | 2014-11-26 | PAION Deutschland GmbH | Novel antibody useful in neurological or neurodegenerative disorders |
| RU2018109230A (ru) * | 2015-08-17 | 2019-09-19 | ДОЙЧЕС ЦЕНТРУМ ФЮР НОЙРОДЕГЕНЕРАТИВЕ ЭРКРАНКУНГЕН е.Ф. (ДЦНЭ) | Антитело, или фрагмент антитела, или неиммуноглобулиновый каркас, связывающийся с областью связывания антитела против рецептора n-метил-d-аспартата (nmda) |
| WO2019246071A1 (en) | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| WO2020204977A1 (en) | 2019-03-29 | 2020-10-08 | Lankenau Institute For Medical Research | Anti-nmda receptor antibodies and methods of use |
| EP3999850A1 (en) | 2019-07-16 | 2022-05-25 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) | Nmda receptor constructs to detect and isolate nmdar autoantibodies |
| WO2021241616A1 (ja) | 2020-05-27 | 2021-12-02 | アステラス製薬株式会社 | 抗ヒトｎｒ１抗体誘導体 |
| CN114891091B (zh) | 2022-06-13 | 2024-04-26 | 四川携光生物技术有限公司 | 一种抗nmdar脑炎重组抗原及应用 |
| AU2024242885A1 (en) | 2023-03-30 | 2025-09-11 | Arialys Therapeutics, Inc. | Detection of autoantibodies against nr1 |
-
2021
- 2021-05-26 WO PCT/JP2021/019929 patent/WO2021241616A1/ja not_active Ceased
- 2021-05-26 CA CA3180470A patent/CA3180470A1/en active Pending
- 2021-05-26 JP JP2022526603A patent/JPWO2021241616A1/ja active Pending
- 2021-05-26 KR KR1020227045463A patent/KR20230029671A/ko active Pending
- 2021-05-26 IL IL298537A patent/IL298537A/en unknown
- 2021-05-26 CN CN202510915556.1A patent/CN120737200A/zh active Pending
- 2021-05-26 AU AU2021281828A patent/AU2021281828A1/en active Pending
- 2021-05-26 MX MX2022014856A patent/MX2022014856A/es unknown
- 2021-05-26 BR BR112022023931A patent/BR112022023931A2/pt unknown
- 2021-05-26 EP EP21812316.4A patent/EP4159859A4/en active Pending
- 2021-05-26 CN CN202180058596.9A patent/CN116133684B/zh active Active
-
2022
- 2022-11-17 US US18/056,635 patent/US20230220070A1/en active Pending
-
2024
- 2024-12-13 US US18/981,054 patent/US12331113B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021241616A5 (https=) | ||
| TWI856979B (zh) | 三特異性抗ｃｄ３８、抗ｃｄ２８和抗ｃｄ３結合蛋白和用於治療病毒感染的使用方法 | |
| US20220226495A1 (en) | Bivalent, bispecific binding proteins for prevention or treatment of hiv infection | |
| CN114746440B (zh) | 新型多肽复合物 | |
| DK2146745T3 (en) | Penta-specific antibody | |
| JP2018502050A5 (https=) | ||
| CN111995681B (zh) | 抗tigit的抗体、其制备方法和应用 | |
| WO2021174595A1 (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
| CN109641046A (zh) | 单链可变片段cd3结合蛋白质 | |
| RU2012112829A (ru) | Анти-gitr-антитела | |
| JP2020505927A5 (https=) | ||
| RU2007129676A (ru) | Антитела к рецептору альфа 1 il-13 и их применение | |
| US20240209082A1 (en) | Anti-cd96 antibodies and methods of use thereof | |
| JP2021507698A5 (https=) | ||
| JP7533897B2 (ja) | 融合タンパク質およびその使用 | |
| JP2005528914A5 (https=) | ||
| AU2014306649A1 (en) | Antibodies to Plasminogen Activator inhibitor-1 (PAI-1) and uses thereof | |
| CN114751987B (zh) | 一种中和冠状病毒的多特异性抗体 | |
| JPWO2022224997A5 (https=) | ||
| WO2021174594A1 (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
| CN105916520A (zh) | Rsv特异性抗体及其功能部分 | |
| JP2022079486A5 (https=) | ||
| JPWO2022102768A5 (https=) | ||
| JP2024530325A5 (https=) | ||
| WO2024125667A1 (zh) | 一种针对SARS-CoV或SARS-CoV-2的单克隆抗体、其制备方法及应用 |